Quantum Biopharma (NASDAQ:QNTM) Issues Earnings Results, Misses Estimates By $2.09 EPS

Quantum Biopharma (NASDAQ:QNTM) posted its earnings results on Friday. The company reported ($2.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($2.09), Zacks reports.

Quantum Biopharma Price Performance

Shares of NASDAQ QNTM traded up $2.69 during midday trading on Friday, reaching $11.07. 8,900,068 shares of the company traded hands, compared to its average volume of 1,189,524. The stock has a 50-day moving average price of $6.09 and a 200 day moving average price of $5.01. The company has a market cap of $21.25 million, a price-to-earnings ratio of -0.75 and a beta of 0.37. Quantum Biopharma has a 52 week low of $2.70 and a 52 week high of $18.00.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.